Phathom Pharmaceuticals, Inc. (PHAT) stock
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.06−0.17 (-2.73%)
Close on Nov 13, 2026Market cap $492.63MP/E –Yield –
Phathom Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Phathom Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $31.82M, down 6.0% year over year. For fiscal 2025 it was $32.78M, down 3.8% from the year before. The highest annual figure on record is $98.15M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.78M | -3.8% |
| FY2024 | Dec 31, 2024 | $34.08M | -31.7% |
| FY2023 | Dec 31, 2023 | $49.90M | -30.2% |
| FY2022 | Dec 31, 2022 | $71.44M | -1.2% |
| FY2021 | Dec 31, 2021 | $72.34M | -26.3% |
| FY2020 | Dec 31, 2020 | $98.15M | +381.7% |
| FY2019 | Dec 31, 2019 | $20.37M | +101770.0% |
| FY2018 | Dec 31, 2018 | $20.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.75M | +24.4% |
| Q2 FY2026 | Jun 30, 2026 | $7.81M | -13.9% |
| Q1 FY2026 | Mar 31, 2026 | $7.77M | -15.4% |
| Q4 FY2025 | Dec 31, 2025 | $7.49M | -12.7% |
| Q3 FY2025 | Sep 30, 2025 | $7.03M | -19.2% |
| Q2 FY2025 | Jun 30, 2025 | $9.08M | +23.0% |
| Q1 FY2025 | Mar 31, 2025 | $9.18M | -2.6% |
| Q4 FY2024 | Dec 31, 2024 | $8.58M | -35.9% |
| Q3 FY2024 | Sep 30, 2024 | $8.69M | -29.1% |
| Q2 FY2024 | Jun 30, 2024 | $7.38M | -42.2% |
| Q1 FY2024 | Mar 31, 2024 | $9.43M | -17.8% |
| Q4 FY2023 | Dec 31, 2023 | $13.39M | -16.0% |
| Q3 FY2023 | Sep 30, 2023 | $12.26M | -35.5% |
| Q2 FY2023 | Jun 30, 2023 | $12.76M | -32.2% |
| Q1 FY2023 | Mar 31, 2023 | $11.48M | -35.0% |
| Q4 FY2022 | Dec 31, 2022 | $15.95M | +17.7% |
| Q3 FY2022 | Sep 30, 2022 | $19.02M | +14.5% |
| Q2 FY2022 | Jun 30, 2022 | $18.82M | -12.9% |
| Q1 FY2022 | Mar 31, 2022 | $17.66M | -14.2% |
| Q4 FY2021 | Dec 31, 2021 | $13.55M | -67.5% |
| Q3 FY2021 | Sep 30, 2021 | $16.61M | -35.6% |
| Q2 FY2021 | Jun 30, 2021 | $21.60M | +45.3% |
| Q1 FY2021 | Mar 31, 2021 | $20.58M | +29.7% |
| Q4 FY2020 | Dec 31, 2020 | $41.65M | +227.9% |
| Q3 FY2020 | Sep 30, 2020 | $25.77M | +476.6% |
| Q2 FY2020 | Jun 30, 2020 | $14.86M | +436.0% |
| Q1 FY2020 | Mar 31, 2020 | $15.87M | +3598.1% |
| Q4 FY2019 | Dec 31, 2019 | $12.70M | +90642.9% |
| Q3 FY2019 | Sep 30, 2019 | $4.47M | +74383.3% |
| Q2 FY2019 | Jun 30, 2019 | $2.77M | – |
| Q1 FY2019 | Mar 31, 2019 | $429.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $14.00K | – |
| Q3 FY2018 | Sep 30, 2018 | $6.00K | – |
See a number that looks wrong?